Management of Stage 3b CKD with Proteinuria and Hyperglycemia

Proteinuria Management

The American College of Physicians and KDIGO recommend ACE inhibitor or ARB therapy for all patients with CKD and urine albumin excretion >300 mg/24 hours, regardless of diabetes status, to slow progression of kidney disease 1, 2
The KDIGO guidelines specifically recommend ARB or ACE-I use in both diabetic and non-diabetic adults with CKD and proteinuria >300 mg/24 hours to slow progression 1, 3
The National Kidney Foundation advises against combining ACE inhibitors with ARBs, as evidence is insufficient to support dual RAAS blockade and may increase harm 1

The American Heart Association and KDIGO recommend targeting blood pressure ≤130/80 mmHg for patients with CKD and significant proteinuria (≥30 mg/24 hours equivalent) 1, 2, 3
For patients with CKD and albuminuria ≥30 mg/24 hours, KDIGO recommends treating to maintain BP consistently ≤130 mmHg systolic and ≤80 mmHg diastolic 1, 3

The National Kidney Foundation-KDOQI endorses less strict glycemic targets (HbA1c 7-8%) for patients with advanced CKD due to shorter life expectancy, high comorbidity burden, and increased hypoglycemia risk 7
The Endocrine Society notes that HbA1c reliability is compromised in advanced CKD, as anemia, erythropoietin use, uremia, and reduced erythrocyte lifespan can bias HbA1c measurements either high or low 6, 7

The KDIGO guidelines recommend monitoring eGFR and proteinuria 3-4 times per year based on risk stratification for Stage 3b CKD with severe albuminuria 1, 2, 3
The American College of Physicians advises checking renal function and electrolytes within 1-2 weeks after initiating or adjusting RAAS blockade or diuretics 4

The American College of Cardiology recommends statin therapy for all patients with Stage 1-3 CKD to reduce cardiovascular mortality risk 8, 9, 10, 11
The National Kidney Foundation advises sodium restriction to <2 g per day, targeting BMI 20-25 kg/m², smoking cessation, and exercise 30 minutes, 5 times per week 2, 3